Close
Novotech
Jabsco PureFlo 21 Single Use

Dainippon wins manufacturing approval for sleep inducing therapy in Japan

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How Lead Selection Impacts CMC Strategy in Drug Development

The molecule you choose to advance into development doesn't just define your science it defines your entire Chemistry, Manufacturing, and Controls roadmap. This article unpacks how early lead selection decisions ripple through CMC planning, regulatory timelines, and ultimately, your path to the clinic.

Trump Announces 100% US Pharma Tariffs for Patented Drugs

The US pharma tariffs policy has been formalised through...
- Advertisement -

Dainippon Sumitomo Pharma has obtained manufacturing and marketing approval for Zolpidem tartrate tablets 5mg/10mg [DSP] from the Ministry of Health, Labour and Welfare in Japan. Zolpidem tartrate tablets 5mg/10mg [DSP] are film-coated tablets containing 5mg or 10mg of zolpidem tartrate, with a score line on one side, which are indicated for the treatment of Insomnia. The usual adult dose is once daily 5 to 10mg of zolpidem tartrate administered orally immediately before bedtime, the company said. The initial dose for elderly patients is from 5mg once daily and may be adjusted depending on age, symptoms, disease, and should not exceed 10mg once daily.

Latest stories

Related stories

How Lead Selection Impacts CMC Strategy in Drug Development

The molecule you choose to advance into development doesn't just define your science it defines your entire Chemistry, Manufacturing, and Controls roadmap. This article unpacks how early lead selection decisions ripple through CMC planning, regulatory timelines, and ultimately, your path to the clinic.

Trump Announces 100% US Pharma Tariffs for Patented Drugs

The US pharma tariffs policy has been formalised through...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »